Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Chinese Patent Office
Citi
Deloitte
McKesson
Argus Health
Healthtrust
Fuji
Mallinckrodt
AstraZeneca

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,658,678

« Back to Dashboard

Which drugs does patent 8,658,678 protect, and when does it expire?

Patent 8,658,678 protects NUVESSA and is included in one NDA.

This patent has two patent family members in two countries.
Summary for Patent: 8,658,678
Title:Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
Abstract: The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.
Inventor(s): Yang; Meidong (Richmond, CA), Chen; Haigang (Petaluma, CA)
Assignee: Dow Pharmaceutical Sciences, Inc. (Petaluma, CA)
Application Number:12/928,306
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 8,658,678

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF BACTERIAL VAGINOSIS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,658,678

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,893,097 Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water ➤ Try a Free Trial
8,877,792 Compositions for increasing solubility of azole drug compounds that are poorly soluble in water ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Teva
Mallinckrodt
AstraZeneca
McKinsey
Cantor Fitzgerald
US Army
Julphar
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot